오리엔트바이오

002630KOSPI의약품 제조업

39.5 / 100

Reference Date: 2026-04-13

Financial Score11.0 / 40

News Sentiment12.5 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is undervalued vs. peers but ROE is below the industry average. Slightly up 2.6% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Orient Bio operates in the biotechnology infrastructure sector, specializing in SPF egg production, CRO clinical trial services, and the development of bio-experimental equipment and biological materials, while adhering to international standards such as ICH, GLP, and GMP. The biotechnology industry, characterized by high added value and growth potential, is a key focus area for the company, contributing to healthcare, research, and pharmaceutical sectors.

Number of Employees

123people

Average Salary

32.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 14.804.0Point

PBR

0.91Industry Average 1.044.0Point

In line with industry avg

ROE

-16.82Industry Average 4.420.0Point

Well below industry avg

Debt Ratio

12.14Industry Average 11.982.0Point

Higher than industry avg (caution)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲1.1% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼260.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -0.2% (declining, 2yr)

Detailed News Sentiment

3 totalPositive 1Neutral 1Negative 0Average Sentiment Score 50

Positive
탈모 치료 새 패러다임, 모발 재생 신약 ‘OND-1’ 개발 착수
오리엔트바이오는 차세대 정밀 약물전달 기술 기반의 모발 재생 신약 후보 'OND-1' 개발을 고도화하며 임상 진입을 위한 독성평가 단계에 착수했습니다.
Neutral
장재진 오리엔트그룹 회장, 법무부 청소년범죄예방위 서울협 회장 취...
오리엔트그룹 장재진 회장이 법무부 청소년범죄예방위원 서울중앙지역협의회 제16대 회장으로 취임했습니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 552Won52-week high 1,92252-week low 524

1-month return4.0Point

1m +2.60% (slight rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral주주총회소집결의2026-03-31
Neutral주주명부폐쇄기간또는기준일설정2026-03-31
Neutral주식병합결정2026-03-31
Neutral주주총회소집공고2026-03-31
Neutral주식등의대량보유상황보고서(일반)2026-03-20